Cuevas-Olivo R, Alejo-Fuentes LJ, Alejo-Fuentes LF, Campos-Angulo G

Language: Spanish
References: 7
Page: 63-66
PDF size: 87.76 Kb.

ABSTRACT

Introduction: Osteogenesis imperfeta (OI) is defined as a heterogeneous group of hereditary diseases, which present with the presence of bone fragility, frequent fractures, bone deformities and short stature. Treatment with biphosfonates in patients with diagnosis of OI has shown a decrease in the frecuency of fractures, as well as an improvement in vertebral bone density. There is little evidence on quality of life in patients diagnosed with OI treated with bisphosphonates, Therefore this study evaluated the quality of life of patients diagnosed with OI after treatment with bisphosphonates. Material and methods: It is a prospective, deliberate intervention, self-controlled clinical trial. Nine patients with ages between two and thirteen ages and diagnosed with OI were treated with Zolendronic, a quality of life measurement was performed in the patients before and after the application. For measuring the quality of life in the patients we used the PedsQL 4.0 quality of life survey that was applied to both children and parents. Results: In the quality of life survey performed on the parents, an increase was observed in the four dimensions evaluated. In the survey made on the children two dimensions showed a significant increase. The number of fractures decreased after the treatment. Conclusions: There is a correlation between the decrease in the number of fractures and the perception that both parents and children have in the quality of life after treatment with bisphosphonates.

REFERENCES

1. Fano V, Del Pino M, Rodríguez CM, Buceta S, Obregón MG. Osteogénesis imperfecta: estudio de la calidad de vida en los niños. Arch Argent Pediatr. 2013; 111(4): 328-31.

2. Wang Z, Yang Z, Ke Z, Yang S, Shi H, Wang L. Mutations in COL1A1 of type I collagen genes in Chinese patients with osteogenesis imperfecta. J Investig Med. 2009; 57(5): 662-7.

3. Burnei G, Vlad C, Georgescu I, Stefan GT, Dan D. Osteogenesis imperfecta: diagnosis and treatment. J Am Acad Orthop Surgery. 2008; 16: 356-66.

4. Gutiérrez-Díez MP, Molina-Gutiérrez MA, Prieto-Tato L, Parra-García JI, Bueno-Sánchez AM. Osteogénesis imperfecta: nuevas perspectivas. Rev Esp Endocrinol Pediatr. 2013; 4(160): 75-85.

5. Glorieux FH, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers RT. Cyclic administration of pamidronate in children with severe osteogenesis imperfect. N Engl J Med. 1998; 339(14): 947-95.

6. Bachrach LK, Ward LM. Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009; 94(2): 400-9.

7. Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop. 2005; 25(6): 786-91.